The Receptor SIGIRR Suppresses Th17 Cell Proliferation via Inhibition of the Interleukin-1 Receptor Pathway and mTOR Kinase Activation  by Gulen, Muhammet F. et al.
Immunity
ArticleThe Receptor SIGIRR Suppresses Th17 Cell
Proliferation via Inhibition of the Interleukin-1
Receptor Pathway and mTOR Kinase Activation
Muhammet F. Gulen,1,2 Zizhen Kang,1 Katarzyna Bulek,1 Wan Youzhong,1 Tae Whan Kim,1 Yi Chen,3 Cengiz Z. Altuntas,1
Kristian Sass Bak-Jensen,3 Mandy J. McGeachy,3 Jeong-Su Do,1 Hui Xiao,1 Greg M. Delgoffe,4 Booki Min,1
Jonathan D. Powell,4 Vincent K. Tuohy,1 Daniel J. Cua,3,5,* and Xiaoxia Li1,2,5,*
1Department of Immunology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
2Department of Biological, Geological, and Environmental Sciences, Cleveland State University, Cleveland, OH 44115, USA
3Merck Research Laboratories (Schering-Plough Biopharma), 901 California Avenue, Palo Alto, CA 94304, USA
4Sidney-Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 20205, USA
5These authors contributed equally to this work
*Correspondence: daniel.cua@spcorp.com (D.J.C.), lix@ccf.org (X.L.)
DOI 10.1016/j.immuni.2009.12.003SUMMARY
Interleukin-1 (IL-1)-mediated signaling in T cells is
essential for T helper 17 (Th17) cell differentiation.
We showed here that SIGIRR, a negative regulator
of IL-1 receptor and Toll-like receptor signaling, was
induced during Th17 cell lineage commitment and
governed Th17 cell differentiation and expansion
through its inhibitory effects on IL-1 signaling. The
absence of SIGIRR in T cells resulted in increased
Th17 cell polarization in vivo upon myelin oligoden-
drocyte glycoprotein (MOG35-55) peptide immuniza-
tion. Recombinant IL-1 promoted a marked increase
in the proliferation of SIGIRR-deficient T cells under
an in vitro Th17 cell-polarization condition. Impor-
tantly, we detected increased IL-1-induced phos-
phorylation of JNK and mTOR kinase in SIGIRR-
deficient Th17 cells compared to wild-type Th17
cells. IL-1-induced proliferation was abolished in
mTOR-deficient Th17 cells, indicating the essential
role of mTOR activation. Our results demonstrate an
important mechanism by which SIGIRR controls
Th17 cell expansion and effector function through
the IL-1-induced mTOR signaling pathway.
INTRODUCTION
Interleukin-17 (IL-17) is a proinflammatory cytokine that plays an
important role in host defense against infections and is involved
in the pathogenesis of multiple human and animal autoimmune
diseases as well as allergen-specific immune responses (Bettelli
et al., 2006; Dong, 2008; Harrington et al., 2005; Iwakura and
Ishigame, 2006; Kolls and Linde´n, 2004; Mangan et al., 2006;
McGeachy and Cua, 2008; Nakae et al., 2002; Park et al.,
2005; Veldhoen et al., 2006). IL-17 concentrations are elevated
in patients with rheumatoid arthritis (RA), multiple sclerosis
(MS), inflammatory bowel disease (IBD), and asthma (Tzartos
et al., 2008; Matusevicius et al., 1999; Teunissen et al., 1998).54 Immunity 32, 54–66, January 29, 2010 ª2010 Elsevier Inc.Anti-IL-17 inhibition can lead to substantial reduction of chemo-
kine production in the central nervous system (CNS), markedly
reduce experimental autoimmune encephalomyelitis (EAE)
severity, and reverse the progression of active EAE (Kroenke
et al., 2008). The pathogenic role of IL-17 has also been
demonstrated in experiments with IL-17- and IL-17R-deficient
mice, in which various autoimmune disorders, including EAE
and collagen-induced arthritis (CIA), were suppressed (Taylor,
2003; Hofstetter et al., 2005; Gonzalez-Garcı´a et al., 2009). The
main function of IL-17 is to coordinate local tissue inflammation
via the interaction with IL-17 receptor, inducing the expression of
proinflammatory and neutrophil-mobilizing mediators (including
IL-6, G-CSF, TNF-a and IL-1, CXCL1, CCL2, CXCL2, CCL7,
and CCL20), as well as matrix metalloproteases (MMPs) that
allow activated T cells to penetrate extracellular matrix (Fossiez
et al., 1996; Yao et al., 1995; Andoh et al., 2005; Laan et al., 1999;
Kao et al., 2005; Chabaud et al., 2000; Bamba et al., 2003;
Gaffen, 2008; Qian et al., 2007).
CD4+ T helper (Th) lymphocytes are essential in regulating
immune responses and autoimmune and inflammatory
diseases. Upon activation, naive CD4+ T helper cells differentiate
into three effector subsets. Th1 cells are characterized by
production of IFN-gwhich mediates cellular immunity. Th2 cells,
which synthesize IL-4, IL-5, and IL-13, are important in humoral
immunity and allergic responses (McGuirk and Mills, 2002;
Murphy and Reiner, 2002). Th17 cells belong to a third lineage
of CD4+ Th cells, which produce IL-17, IL-17F, IL-21, and IL-22
(Langrish et al., 2005; Bettelli et al., 2006; Harrington et al.,
2005; Iwakura and Ishigame, 2006; Kolls and Linde´n, 2004; Man-
gan et al., 2006; Nakae et al., 2002; Park et al., 2005; Veldhoen
et al., 2006). Several cytokines including TGF-b and IL-6 are
required for Th17 cell differentiation upon T cell receptor (TCR)
activation. Transcription factors including STAT3 together with
RORa and RORgt determine Th17 cell lineage-specific differen-
tiation program through induction of a set of signature cytokines
and cytokine receptors, including IL-23R and IL-1R (Korn et al.,
2007; Wei et al., 2007; Yang et al., 2008; Ivanov et al., 2006;
McGeachy et al., 2007). Although the detailed molecular mech-
anism is still unclear, IL-1 and IL-23 have major influences on
Th17 cell differentiation, possibly through cell proliferation and
survival, to maintain the differentiated state of Th17 cells (Korn
Figure 1. SIGIRR Expression Is Induced during Th17 Cell Ddifferen-
tiation
(A–C) Naive CD4+ T cells (CD4+CD44lo) were sorted by flow cytometry and
polarized under Th1 (IL-12 and anti-IL-4) and Th17 (TGF-b, IL-6, anti-IFN-g,
and anti-IL-4) cell-inducing conditions (on anti-CD3- and anti-CD28-coated
plates) for 3 days, followed by (A) immunoblot analysis for the expression of
SIGIRR, (B) real-time PCR analysis for the expression of IL-1R1 and IL-23R,
and (C) ELISA assay for the production of IL-17 and IFN-g.
(D) Real-time PCR analysis for the expression of IL-17, SIGIRR, IL-1R1,
and IL-23R over the time course of Th17 cell polarization. The presented
data represent three independent experiments. Error bars, SD; *p < 0.05;
**p < 0.01 (two-tailed t test).
Immunity
SIGIRR Suppresses Th17 Cell Proliferationet al., 2009). Importantly, mice lacking either IL-1 or IL-23 are
resistant to disease induction in Th17 cell-dependent CIA,
EAE, and IBD diseases models (Ben-Sasson et al., 2009; Sutton
et al., 2006; Murphy et al., 2003; Thakker et al., 2007; Langrish
et al., 2005; Chung et al., 2009; Brereton et al., 2009). Although
much effort has been focusing on how cytokines promote
Th17 cell differentiation, it is equally critical to investigate how
Th cell effector functions are regulated. Multiple cytokines
including IFN-g, IL-4 (Harrington et al., 2005; Park et al., 2005),
IL-2, and IL-27 (Laurence et al., 2007; Stumhofer et al., 2006)
have been shown to downregulate Th17 cell differentiation
through direct and/or indirect impact on the transcriptional
program mediated by STAT3, RORgt, and RORa. Here, we
demonstrate that SIGIRR, a negative regulator of IL-1 receptor
and Toll-like receptor, suppressed Th17 cell expansion and
IL-17-dependent disease.
SIGIRR (also referred as TIR8) is a negative regulator for IL-1R,
TLR4, and TLR9 signaling. SIGIRR contains a single immuno-
globulin (Ig) extracellular domain and a TIR (Toll-IL-1R) intracel-
lular domain (Garlanda et al., 2004; Wald et al., 2003), inhibiting
IL-1 and lipopolysaccharide (LPS) signaling through its interac-
tionwith the TLR4 and IL-1R complexes (Qin et al., 2005). In addi-
tion to the role of SIGIRR in mucosal immunity (Garlanda et al.,
2004; Xiao et al., 2007), recent studies have shown the critical
role of SIGIRR in modulating autoimmunity and inflammatory
responses associated with infections (Bozza et al., 2008;
Garlanda et al., 2007). SIGIRR is highly expressed in intestinal
epithelial cells, contributing to immune tolerance to commensal
bacteria. Importantly, SIGIRR is also expressed in T cells
and DCs, exerting the fine-tuning modulation in inflammatory
responses,manifestedby thehypersusceptibility of SIGIRR-defi-
cient mice to pathogen infection or autoimmune lupus (Lech
et al., 2008).
Here, we report that whereas SIGIRR expression was induced
in differentiated Th17 cells, SIGIRR-deficient mice were more
susceptible to experimental autoimmune encephalomyelitis
(EAE) resulting from hyperactivation of Th17 cells upon immuni-
zation with MOG (myelin oligodendrocyte glycoprotein) peptide.
IL-1 treatment resulted in increased TGF-b and IL-6-mediated
Th17 cell differentiation in SIGIRR-deficient T cells compared
to that in wild-type T cells, suggesting that the impact of SIGIRR
on Th17 cells is probably through itsmodulation on IL-1 signaling
during Th17 cell differentiation. We also examined IL-1 signaling
mechanism in Th17 cells and detected increased IL-1-induced
phosphorylation of JNK and mTOR kinase in SIGIRR-deficient
Th17 cells compared to wild-type Th17 cells. Rapamycin, an
inhibitor of mTOR, specifically inhibited SIGIRR-regulated IL-1-
induced Th17 cell proliferation and IL-17 production. Taken
together, our study suggests that SIGIRR plays an important
regulatory role in Th17 cell differentiation and proliferation and
IL-17-dependent EAE pathogenesis, probably through its modu-
lation on IL-1 signaling in Th17 cells.
RESULTS
SIGIRR Expression Is Induced during Th17 Cell
Differentiation
Although SIGIRR is expressed in splenic T cells, its physiological
function in T cell is unclear. SIGIRR-deficient mice are highlysusceptible to DSS-induced colitis, and DSS-treated SIGIRR-
deficient colon tissues produce high amounts of IL-17 (Xiao
et al., 2007), implicating a possible regulatory role of SIGIRR
in Th17 cell function. Therefore, we sought to determine the
potential role of SIGIRR in modulation of Th17 cell function.
We found that SIGIRR and the known Th17 cell-associated
molecules (IL-17, IL-1R1, and IL-23R) were expressed at
a much higher amount in Th17 cells compared to IFN-g-
producing Th1 or naive CD4+ T cells, indicating a possible
functional role of SIGIRR in Th17 cell subset (Figures 1A–1C).
A time course was performed to examine the kinetics of SIGIRR
and IL-1R1 expression by real-time PCR during Th17 cellImmunity 32, 54–66, January 29, 2010 ª2010 Elsevier Inc. 55
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on day 1 of polarization, SIGIRR, IL-17, and IL-23R expression
was induced more gradually during polarization, suggesting
a possible feedback regulatory role of SIGIRR for Th17 cell func-
tion (Figure 1D).
SIGIRR Deficiency Leads to Increased Susceptibility
to Th17 Cell-Dependent EAE
IL-1 signaling in T cells is essential in Th17 cell responses in vivo
(Sutton et al., 2006; Ben-Sasson et al., 2009). To determine the
regulatory role of SIGIRR in IL-1-mediated signaling in Th17 cells,
we first examined the impact of SIGIRR deficiency on Th17 cell
effector function in vivo. Compared to WT mice, Sigirr/ mice
showed an earlier onset of neurologic impairment and markedly
increased disease severity compared to WT littermates
(Figure 2A). These data show that SIGIRR is critical for the modu-
lation of MOG35-55-induced EAE in mice. Consistent with the
clinical signs, mononuclear cell infiltrates were more prominent
in the white matter of spinal cords of MOG35-55-immunized
Sigirr/ mice compared to that in WT mice (Figures 2B and
2C). Compared with the brain tissues from WT mice, Sigirr/
mice showed substantially more infiltrating CD45+, CD4+,
CD11b+, and Gr-1+ cells. In addition, the amount of TNF, IL-17,
and IL-6 was increased in the spinal cords of Sigirr/ mice
compared to that in control mice (Figure 2D). Thus, the increased
susceptibility ofSigirr/mice toMOG35-55-induced EAE is asso-
ciated with increased mononuclear cell infiltration in the CNS
during EAE induction and elevated inflammatory cytokines in
the spinal cords.
To determine the effect of SIGIRR deficiency on the activation
of MOG35-55-specific T cells in EAE, we examined responses
of Sigirr/ and WT lymph node cells to MOG35-55 in vitro for
10 days after immunization of mice with MOG35-55. Lymph
node cells from Sigirr/ mice showed higher frequencies of
T cells secreting IL-17, but similar numbers of IFN-g-producing
cells, compared to WT mice (Figure 2E). In the recall responses
toMOG35-55, supernatants from 10-day primed lymph node cells
from Sigirr/mice showed elevated production of IL-17, but not
IFN-g, compared to that in WT mice (Figure 2F). These results
suggest that SIGIRR deficiency enhances Th17 cell polarization
in vivo. The functionality of MOG-specific Th17 cells from the
WT and Sigirr/ mice was further compared by adoptive trans-
fer to WT and Sigirr/ recipient mice to induce EAE. Adoptive
transfer of MOG35-55-specific Sigirr
/ Th17 cells induced
more severe EAE in either WT or Sigirr/ recipient mice
compared toWT Th17 cells (Figure 2G). Thus, SIGIRR deficiency
enhances Th17 cell polarization in vivo, leading to increased
severity of IL-17-dependent EAE.
SIGIRR Directly Regulates Th17 but Not Th1 Cell
Development
To test the intrinsic role of SIGIRR in T cells, we sorted naive
T cells (CD4+CD44lo) fromWT and Sigirr/mice and transferred
them into Rag1/ mice. Upon immunization with MOG35-55,
mice with Sigirr/ T cells developed more severe EAE than
did the mice with WT T cells (Figure 3A). Consistent with the
clinical scores, inflammatory cell infiltration and secretion of
inflammatory cytokines were significantly increased in the spinal
cord of the Rag1/ recipient mice transferred with Sigirr/56 Immunity 32, 54–66, January 29, 2010 ª2010 Elsevier Inc.T cells compared to that in the mice transferred with WT
T cells (Figures 3B and 3C). Elevated IL-17 mRNA expression
in the spinal cord of mice with Sigirr/ T cells supports the regu-
latory role of SIGIRR on Th17 cell differentiation and expansion
(Figure 3C). To confirm that T cell-derived SIGIRR has an intrinsic
impact on Th17 cell development, we examined whether T cell-
specific expression of SIGIRR is able to rescue the hyper Th17
cell activation in Sigirr/ mice. We generated T cell-specific
SIGIRR-transgenic mice by using the CD2 promoter to drive
the overexpression of SIGIRR, and we crossed CD2-SIGIRR
onto Sigirr/ mice to generate SIGIRR-TG-KO mice (Figure S1
available online; Lang et al., 1988) In the recall responses to
MOG35-55, supernatants from 10-day primed lymph node cells
from SIGIRR-TG-KO mice showed reduced production of IL-17
compared to Sigirr/ mice (Figure 3D). Consistent with ELISA
data, the number of MOG35-55-specific IL-17-producing cells,
but not IFN-g-producing cells, was decreased in SIGIRR-TG-
KO mice as compared to that in Sigirr/ mice (Figure 3E).
Thus, T cell-specific expression of SIGIRR is able to rescue the
hyper Th17 cell activation in Sigirr/ mice.
To further determine whether SIGIRR has direct impact on
Th17 cells, we cocultured naive T cells from WT and Sigirr/
mice with WT splenic DCs and differentiated them into Th1
and Th17 cell lineages. The frequency of IFN-g-positive cells
as well as amount of secreted IFN-g from Th1 cell differentiated
cultures was indistinguishable between WT and Sigirr/
cells (Figure 3F), suggesting that SIGIRR does not have a
substantial impact on Th1 cell differentiation. Furthermore,
similar amounts of IFN-g were detected in WT and Sigirr/
Th1 cells in response to IL-18 stimulation (Figure 3G). In contrast,
the frequency of IL-17-positive cells and total IL-17 production
were significantly increased in Sigirr/ Th17 cells compared
to WT (Figures 3F and 3H). In addition to IL-17, the expression
of other Th17 cell-associated molecules (including IL-17, IL-22,
and IL-23R) was also higher in Sigirr/ Th17 cells than that in
WT cells (Figure 3I). Thus, SIGIRR directly regulates Th17 but
not Th1 cell development.
SIGIRR Suppresses Th17 Cell Differentiation
and Proliferation through IL-1R Signaling
IL-1 signaling in T cells synergizes with IL-6 to regulate Th17
cell differentiation and maintain cytokine production in effector
Th17 cells (Chung et al., 2009). To confirm the role of IL-1
signaling in Th17 cell differentiation and maintenance, we
purified naive T cells from WT and Il1r1/ mice and differenti-
ated them into Th17 cells (TGF-b+IL-6) with or without IL-1b.
IL-1b indeed enhanced Th17 cell differentiation, which was
abolished in the absence of IL-1R (Figure 4A). SIGIRR inhibits
IL-1R-TLR signaling through its interaction with the receptor
complexes. We hypothesize that the impact of SIGIRR on
Th17 cell differentiation and proliferation is due to enhanced
IL-1R signaling in these cells. To test this hypothesis, WT and
Sigirr/ naive T cells were differentiated into Th17 cells with
or without IL-1b stimulation. Similar numbers of IL-17-positive
cells (8%–10%) were detected in WT and Sigirr/ T cells
under TGF-b+IL-6-mediated differentiation condition (in the
absence of IL-1b stimulation) (Figure 4B). Importantly, although
IL-1b promoted Th17 cell differentiation in both WT and
Sigirr/ T cells, addition of IL-1b resulted in a significantly
Figure 2. SIGIRR Deficiency Leads to Increased Susceptibility of Th17 Cell-Dependent EAE and Hyperactivation of MOG-Specific Th17 Cells
(A) EAE was induced by MOG35-55 immunization. Mean clinical scores were calculated each day for WT (n = 13) and Sigirr
/ (n = 10) mice.
(B) Hematoxylin and eosin and anti-CD3 staining of spinal cord of WT and Sigirr/ mice 15 days after immunization with MOG35-55.
(C) Immune cell infiltration in the brain of MOG35-55 immunized WT and Sigirr
/ mice (n = 3, 7 days after disease onset) was analyzed by flow cytometry.
(D) Real-time PCR analysis of relative expression of IFN-g, IL-17, TNF-a, and IL-6 in spinal cords ofMOG35-55 immunizedWT andSigirr
/mice (n = 3, 7 days after
disease onset) as compared to CFA-treated WT control mice. Error bars, SD; *p < 0.05 (two-tailed t test). Data are representative of three independent exper-
iments.
(E and F) Draining lymph node cells fromwild-typemice andSigirr/mice were collected 10 days after immunization with either MOG35-55 emulsified in complete
Freund’s adjuvant or complete Freund’s adjuvant alone andwere restimulated withMOG35-55 in vitro for 4 days, followed by ELISPOT analysis (E) and ELISA (F) of
IL-17 and IFN-g. Error bars, SD; n = 10 mice per group. **p < 0.01 (two-tailed t test).
(G) Primed MOG35-55 specific T cells (10 days) were restimulated with MOG35-55 in vitro in the presence of recombinant IL-23 for 4 days, and then transferred to
naive wild-type and Sigirr/ mice. Graph represents the average clinical score after T cell transfer. n = 5. *p < 0.05 (ANOVA). Data are representative of three
independent experiments.
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Figure 3. T Cell-Derived SIGIRR Regulates Th17 Cell Development In Vivo
Wild-type and Sigirr/ naive T cells were intravenousely transferred into Rag1/ mice and EAE was induced by MOG35-55 immunization.
(A) Mean clinical scores were calculated each day for Rag1/ mice transferred with wild-type and Sigirr/ T cells. n = 5; *p < 0.05 (ANOVA).
(B) Hematoxylin and eosin staining of spinal cord of Rag1/ mice transferred with wild-type and Sigirr/ T cells 15 days after immunization with MOG35-55.
(C) Real-time PCR analysis of relative expression of IFN-g, IL-17, TNF-a, and IL-6 in spinal cords ofMOG35-55-immunizedRag1
/mice transferredwith wild-type
and Sigirr/ T cells (n = 3, 10 days after disease onset).
(D and E) Draining lymph node cells from SIGIRR-TG-KO (TG-KO) and littermate Sigirr/mice were collected 10 days after immunization with MOG35-55 emul-
sified in complete Freund’s adjuvant and were restimulated with MOG35-55 in vitro for 4 days, followed by ELISA (D) and ELISPOT analysis (E) (see also Figure S1).
Error bars, SD; *p < 0.05 (two-tailed t test). Data are representative of three independent experiments.
(F–H) Naive T cells (CD4+CD44lo) fromwild-type andSigirr/mice were coculturedwith wild-type splenic antigen-presenting cells (APCs) in the presence of anti-
CD3 and polarized them under Th1 (IL-12 and anti-IL-4) or Th17 (TGF-b, IL-6, anti-IFN-g, and anti-IL-4) cell conditions, followed by intracellular cytokine staining
for IL-17 and IFN-g (F) and ELISA for IL-17 (H).
(G) Wild-type and Sigirr/ mice Th1 cells were treated with 5 ng/ml IL-18 for 48 hr, followed by ELISA for IFN-g.
(I) Real-time PCR analysis of relative expression of IL-17, IL-22, IL-23R, ROR-gt, and IL-10 in wild-type and Sigirr/ Th17 cells as compared to naive T cells.
Data are representative of at least three (A–C) independent experiments. Error bars (A–C), SD; *p < 0.05; **p < 0.01 (two-tailed t test).
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Figure 4. SIGIRR Suppresses Th17 Cell
Differentiation and Expansion through IL-
1R Signaling
(A) Naive wild-type and Il1r1/ CD4+ T cells
(CD4+CD44lo) were polarized to Th17 cells
(TGFb+IL-6 on anti-CD3- and anti-CD28-coated
plates) in the presence and absence of IL-1b,
followed by ELISA for IL-17 and IL-22.
(B) Naive wild-type and Sigirr/ CD4+ T cells
(CD4+CD44lo) were polarized to Th17 cells
(TGFb+IL-6 on anti-CD3- and anti-CD28-coated
plates) in the presence and absence of IL-1b,
followed by intracellular cytokine staining for
IL-17 and IFN-g. Whereas IL-1b promoted Th17
cell differentiation in both WT and Sigirr/
T cells, addition of IL-1b resulted in a significantly
higher IL-17-positive population in Sigirr/
T cells than that in WT T cells.
(C) Real-time PCR analysis of relative expression
of IL-17, IL-22, IL-21, IL-23R, ROR-gt, IL-10, and
IRF4 in wild-type and Sigirr/ Th17 cells as
compared to the naive T cells.
Data are representative of at least three separate
experiments. Error bars, SEM. *p < 0.05;
**p < 0.01 (two-tailed t test).
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SIGIRR Suppresses Th17 Cell Proliferationhigher IL-17-positive population in Sigirr/ T cells than that in
WT T cells (Figure 4B). Consistent with flow cytometry analysis,
the expression of other Th17 cell-associated molecules
(including IL-17, IL-21, IL-22, and IL-23R) was also much higher
in Sigirr/ T cells than that in WT cells in the presence of IL-1b
stimulation (Figure 4C). In addition, consistent with IL-1 induc-
tion of transcription factor IRF4 and RORgt expression, SIGIRR
deficiency significantly enhanced the expression of IRF4
and RORgt during Th17 cell differentiation (Figure 4C). Thus,
SIGIRR negatively regulates Th17 cell differentiation and prolif-
eration by suppressing IL-1R signaling during differentiation of
Th17 cells.Immunity 32, 54–6SIGIRR Deficiency Leads to
Increased IL-1-Induced JNK and
mTOR Phosphorylation
To understand the molecular mechanism
by which SIGIRR regulates IL-1-depen-
dent Th17 cell differentiation and prolifer-
ation, we examined IL-1 signaling in WT
and Sigirr/ Th17 cells. Although IL-1
stimulation induced p38 and IkBa phos-
phorylation in both WT and Sigirr/
Th17 cells, IL-1 treatment leads to
increased JNK and mTOR phosphoryla-
tion in Sigirr/ Th17 cells compared to
that in WT cells (Figure 5A). Consistent
with this, IL-1-dependent phosphoryla-
tion of 4E-BP1 (eukaryotic initiation factor
4E-binding protein, an mTOR substrate)
and S6 (a downstream component of
mTOR signaling) were also increased in
Sigirr/ Th17 cells compared to that in
WT cells. Thus, SIGIRR deficiency mark-edly enhances at least some of the IL-1-mediated signaling
cascades in Th17 cells.
To determine the impact of SIGIRR-modulated IL-1-induced
signaling events on Th17 cell effector function, we used specific
inhibitors to block these IL-1-induced signaling cascades in WT
and Sigirr/ Th17 cells, including inhibitors for mTOR (rapamy-
cin), p38 (SB203580), and JNK (SP600125). All three inhibitors
significantly reduced IL-1-induced IL-17 production in both WT
and Sigirr/ Th17 cells, indicating the importance of mTOR,
JNK, and p38 activation for IL-1-induced Th17 cell effector
function (Figure 5B). Although the inhibitors of p38 and JNK
decreased IL-1-induced IL-17 production in both WT and6, January 29, 2010 ª2010 Elsevier Inc. 59
Figure 5. SIGIRR Suppresses Th17 Cell Expansion through IL-1-Induced mTOR-Mediated Cell Proliferation
(A) Cell lysates fromwild-type andSigirr/ Th17 cells untreated or treatedwith IL-1 (10 ng/ml) for different time points were analyzed by immunoblot analysis with
antibodies as indicated.
(B) Wild-type and Sigirr/ Th17 cells were rested for 2 days, followed by incubation with different doses of IL-1 as indicated in the presence or absence of 50 nM
rapamycin, 2 mM SB203580, or 10 mM SP600125 for 3 days. The treated cells were analyzed for production of IL-17 by ELISA.
(C) Cell lysates from Sigirr/ Th17 cells pretreated with rapamycin for 2 hr and then treated IL-1 (10 ng/ml) treatment for 15, 30, and 60 min were analyzed by
immunoblot analysis with antibodies as indicated.
(D) Wild-type and Sigirr/ Th17 cells were rested for 2 days, followed by incubation with different doses of IL-1. The treated cells were incubated 1 additional day
with 3H for thymidine incorporation experiment.
(E) Frap1fl/fl naive CD4+ T cells were differentiated into Th17 cells and infectedwith retrovirus expressingGFP or Cre/GFP. Infected CD4+GFP+ cells were isolated,
analyzed for mTOR expression (left), and cultured in the presence and absence of IL-1. GFP+ cells were analyzed by thymidine incorporation assay for prolifer-
ation (right). Error bars, SD; *p < 0.05; **p < 0.01 (two-tailed t test). Data are representative of three independent experiments.
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IL-17 in the presence of either inhibitor compared to WT cells.
In contrast, the impact of SIGIRR deficiency on Th17 cell effector
function was abolished after rapamycin treatment (Figure 5B).
Similar residual amounts of IL-17 production were detected in
IL-1-stimulated WT and Sigirr/ Th17 cells after rapamycin60 Immunity 32, 54–66, January 29, 2010 ª2010 Elsevier Inc.treatment, suggesting that the mTOR-mediated signaling is crit-
ical for SIGIRR to modulate IL-1-dependent Th17 cell effector
function. The inhibitory effect of rapamycin is specific for the
mTOR pathway because rapamycin treatment inhibited the
IL-1-induced 4E-BP1 and S6 but not JNK phosphorylation
(Figure 5C).
Immunity
SIGIRR Suppresses Th17 Cell ProliferationBecause mTOR signaling is known to have a major impact on
cell growth and proliferation, we examined WT and Sigirr/
Th17 cell proliferation in response to IL-1 stimulation. Whereas
IL-1 induced proliferation in both WT and Sigirr/ Th17 cells,
the IL-1-induced cell proliferation was much higher in Sigirr/
Th17 cells than that inWTcells (Figure 5D). These results strongly
suggest that SIGIRR deficiency has a substantial impact on
Th17 cell proliferation, which leads to increased production of
cytokines associated with Th17 cells. Importantly, rapamycin
abolished IL-1-induced cell proliferation in bothWT and Sigirr/
Th17 cells. Thus, one important mechanism for SIGIRR to
suppress Th17 cell proliferation and effector function is through
IL-1-induced mTOR-mediated cell proliferation. To exclude the
possible nonspecific effect of rapamycin, we examined the
responsiveness of WT and mTOR-deficient Th17 cells to IL-1
stimulation. Because Frap1/ T cells are unable to differentiate
into Th17 cells, we first differentiated Frap1fl/fl (wild-type) naive
T cells into Th17 cells. The differentiated Th17 cells (Frap1fl/fl)
were infected with hCre-GFP-RV to delete mTOR (Figure 5E;
Delgoffe et al., 2009; Zhu et al., 2004). Whereas IL-1 stimulation
increased the proliferation of WT Th17 cells, the proliferation of
mTOR-deficient cells was abolished in response to IL-1 treat-
ment (Figure 5E). Thus, IL-1-induced Th17 cell expansion is
mTOR dependent.
SIGIRR-Modulated IL-1-Activated mTOR Pathway
Signals through the IRAK Proteins
We next investigate how SIGIRR modulates IL-1-mediated
mTOR activation. Upon IL-1 stimulation, adaptor MyD88 is
recruited to the IL-1 receptor, followed by the recruitment of
serine and threonine kinases IRAK4 and IRAK1 (interleukin-1
receptor-associated kinases) (Yao et al., 2007). At the receptor
complex, IRAK4 mediates the phosphorylation of IRAK1, fol-
lowed by the ubiquitination and degradation of IRAK1, which
are crucial for the activation of downstream signaling cascades
(Yao et al., 2007). We have previously shown that SIGIRR
negatively regulates IL-1 signaling through its interaction with
the receptor complex, attenuating the recruitment of these
receptor proximal signaling components to the receptor
(including MyD88, IRAK4, and IRAK1) (Qin et al., 2005). Consis-
tent with this, we found that IRAK1 degradation was accelerated
in Sigirr/ Th17 cells in response to IL-1 stimulation, demon-
strating the impact of SIGIRR deficiency on IL-1-induced
IRAK1 activation in Th17 cells (Figure 5A).
We and others have recently reported that IRAK4 and IRAK1
are required for Th17 cell polarization and development of EAE
(Staschke et al., 2009). Therefore, we wondered whether SIGIRR
modulates IL-1-mediated mTOR activation and the IL-1-depen-
dent Th17 cell proliferation through the IRAK proteins. To test
this hypothesis, we examined the impact of IRAK4 and IRAK1
deficiency on IL-1-induced mTOR signaling and IL-1-dependent
Th17 cell development. IL-1-induced phosphorylation of mTOR,
4EBP, and S6were all abolished in IRAK4-deficient Th17 cell and
greatly reduced in IRAK1-deficient Th17 cells (Figure 6A), indi-
cating that IRAK4 and IRAK1 are indeed required for IL-1-
induced activation of mTOR and its downstream signaling
components. Consistent with this, IL-1-induced Th17 cell prolif-
eration was significantly reduced in IRAK4- and IRAK1-deficient
Th17 cells, implicating the importance of IRAK4 and IRAK1-mediatedmTOR activation in IL-1-induced Th17 cell proliferation
(Figure 6B). Taken together, these results suggest that SIGIRR
modulates Th17 cell expansion through the IRAK4-IRAK1-
mTOR pathway. Interestingly, IRAK4 and IRAK1 were required
for IL-1-induced mTOR and JNK but not p38 activation
(Figure 6A). Consistent with this, SIGIRR preferentially affected
mTOR and JNK activation, but not p38, in response to IL-1 stim-
ulation, which further supports the notion that SIGIRRmodulates
IL-1-mediated downstream signaling through its impact on the
activation of IRAK4 and IRAK1 (Figure 6A)
The tuberous sclerosis 1 (TSC1)-TSC2 tumor suppressor
complex serves as a repressor of the mTOR pathway, and the
disruption of TSC1-TSC2 complex leads to mTOR activation
(Lee et al., 2007). We found that IL-1 stimulation can also lead
to disruption of TSC1-TSC2 complex in human 293 cells trans-
fected with IL-1R (293-IL-1R). Importantly, IL-1-mediated
disruption of TSC1-TSC2 complex was greatly reduced in
IRAK1-deficient cells derived from 293-IL-1R cells (Li et al.,
1999), suggesting that IRAK1-dependent mTOR activation is
through the disruption of TSC1-TSC2 complex (Figure 6C). Over-
expression of SIGIRR suppressed the IL-1-induced disruption of
TSC1-TSC2 complex, which is probably due to the inhibitory
effect of SIGIRR on IRAK1 activation (as evident by reduced
IRAK1 modification upon SIGIRR overexpression) (Figure 6C).
Taken together, these results suggest that SIGIRR modulates
IL-1-induced mTOR activation through its impact on IRAK1 acti-
vation and consequent effect on IRAK1-mediated disruption of
TSC1-TSC2 complex.
DISCUSSION
We report here amechanism for the regulation of Th17 cell differ-
entiation and expansion. IL-1-mediated signaling in T cells is
essential for in vivo Th17 cell differentiation and IL-17-dependent
autoimmune diseases. We showed here that SIGIRR is induced
during Th17 cell differentiation and it suppresses Th17 cell differ-
entiation and proliferation through direct inhibition of multiple
IL-1-dependent signaling pathways. IL-1-induced phosphoryla-
tion of JNK and mTOR is enhanced in Sigirr/ Th17 cells.
Rapamycin, an inhibitor of mTOR, specifically blocked SIGIRR-
regulated IL-1-induced Th17 cell proliferation and cytokine
production. Importantly, IL-1-dependent proliferation was abol-
ished in mTOR-deficient Th17 cells, confirming the essential role
of mTOR activation in IL-1-dependent Th17 cell proliferation. We
also showed that SIGIRR is critical for the control of Th17 cell-
dependent development of CNS autoimmune inflammation. In
the absence of this IL-1 regulatory mechanism, Th17 cells infil-
trated the CNS in greater numbers and showed enhanced
pathogenic functions. Thus, SIGIRR belongs to a class of
immune modulators, including IL-2, IL-4, IL-25, IL-27, IFN-g,
IFN-a, and ATAR, capable of suppressing the development
and function of IL-17-producing T cells.
Both IL-1R1 and IL-23R are induced by IL-6-dependent
RORgt expression (Chung et al., 2009). Although stimulation
with TGF-b and IL-6 is sufficient to drive the initial development
of IL-17-producing T cells in vitro, Il1r1/ T cells can not differ-
entiate into inflammatory Th17 cells in vivo. Accordingly, IL-1
signaling in T cells is absolutely essential for the induction of
autoimmune encephalomyelitis (Sutton et al., 2006; ChungImmunity 32, 54–66, January 29, 2010 ª2010 Elsevier Inc. 61
Figure 6. IL-1 Activates mTOR Pathway through IRAK Proteins
(A) Cell lysates from wild-type, Irak4/, and Irak1/ Th17 cells untreated or treated with IL-1 (10 ng/ml) for different time points were analyzed by immunoblot
analysis with antibodies as indicated.
(B) Naive wild-type, Irak4/, and Irak1/CD4+ T cells (CD4+CD44lo) were polarized to Th17 cells (TGF-b+IL-6 on anti-CD3- and anti-CD28-coated plates) in the
presence and absence of IL-1b, followed by intracellular cytokine staining for IL-17 and IFN-g. Error bars, SD; *p < 0.05; **p < 0.01 (two-tailed t test).
(C) 293 cells transfected with IL-1R (293-IL-1R) cells, IRAK1-deficient cells, and 293-IL-1R transfected with SIGIRRwere treated or untreated with IL-1 for 15min.
TSC1/TSC2 protein complexwas immunoprecipitated and analyzed by immunoblot analysiswith antibodies as indicated. Data are representative of at least three
independent experiments.
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SIGIRR Suppresses Th17 Cell Proliferationet al., 2009). In support of this, IRAK4 (a key kinase in IL-1
signaling) kinase-inactive (IRAK4 KI) Th17 cells fail to induce
EAE in either WT or IRAK4 KI recipient mice (Staschke et al.,
2009). In contrast, WT Th17 cells are able to induce EAE in
both WT and IRAK4 KI recipient mice, indicating that IL-1
signaling in the CNS resident cells is not essential for IL-1-
dependent induction of EAE disease. Further evidence support-
ing a direct effect of IL-1 on T cells came from adoptive transfer
of OVA-TCR transgenic T cells into Il1r1/ recipients, which
demonstrate that T cells are a major target of IL-1 in vivo (Ben-
Sasson et al., 2009). In addition, deficiency of IL-1R1 on T cells
but not on DCs blocked Th17 cell polarization (Chung et al.,
2009). Consistent with these previous results, we found that
the lack of SIGIRR on T cells leads to increased autoantigen-
induced Th17 cell polarization in vivo. Importantly, Th17 cell
differentiation and cytokine production were significantly
increased inSigirr/ T cells after theywere polarized in the pres-62 Immunity 32, 54–66, January 29, 2010 ª2010 Elsevier Inc.ence ofWTDCs, indicating that deficiency of SIGIRR on T cells—
not DCs—results in increased Th17 cell development. It is also
noteworthy that WT Th17 cells were able to induce similar EAE
severity in both WT and Sigirr/ recipients, demonstrating that
SIGIRR deficiency does not have a major impact on the
responses of APCs and CNS resident cells to autoantigen-
specific Th17 cells.
Recent studies have shown that IL-1 stimulation enhances the
expression of transcription factors IRF4 and RORgt, indicating
that IL-1 is capable of directly influencing Th17 cell differentiation
(Chung et al., 2009). It is thought that naive T cell-derived TGF-b
in the presence of exogenous IL-6 is sufficient to initiate the
RORgt-dependent gene expression program of Th17 cells.
However, further stabilization of the Th17 cell program is
required for their in vivo function. We and others have demon-
strated that two additional signaling pathways are essential for
this stabilizing effect; these include the IL-1R and IL-23R
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SIGIRR Suppresses Th17 Cell Proliferationpathways (Chung et al., 2009; McGeachy and Cua, 2007, 2008).
Consistent with the concept that SIGIRR has a central role in
Th17 cell differentiation through the regulation of IL-1 signaling,
SIGIRR deficiency did not impact Th17 cell differentiation
induced by TGF-b+IL-6 in vitro. It is only in the presence of exog-
enous IL-1 (TGF-b+IL-6+IL-1) that we observed enhanced Th17
cell proliferation and cytokine production in Sigirr/ T cells. Our
findings also suggest that SIGIRR negatively regulates Th17 cell
differentiation and proliferation by suppressing IL-1 signaling
during initial differentiation of Th17 cells as well as in differenti-
ated effector Th17 cells. Furthermore, the absence of SIGIRR
regulation enabled the overexpression of IRF4 and RORgt that
is mediated by IL-1 in the presence of TGF-b and IL-6, which
might account for the increased expression of IL-17 and other
Th17 cell-associated cytokines in Sigirr/ T cells. Hence our
findings are consistent with the known effects of IL-1 on Th17
cell transcriptional regulation, where SIGIRR is a key regulator
to prevent overactivation of Th17 cell-mediated pathogenic
effects.
What specific IL-1-mediated signaling events are critical for
Th17 cell differentiation and effector function and how they are
modulated by SIGIRR? Although IL-1 induced similar amounts
of p38 phosphorylation in WT and Sigirr/ Th17 cells, SIGIRR
deficiency allowed greater IL-1-induced phosphorylation of
JNK, mTOR, and 4E-BP1 (a substrate of mTOR). We showed
that the inhibitors of p38, JNK, and mTOR all decreased IL-1-
induced IL-17 production in both WT and Sigirr/ Th17 cells.
However, only rapamycin abolished the impact of SIGIRR defi-
ciency on Th17 cell effector function, indicating the critical role
of mTOR pathway for SIGIRR-mediated modulation on Th17
cell function. In addition, the mTOR-activated pathways have
been linked to cell cycle progression and indeed, IL-1 induced
more Th17 cell proliferation in Sigirr/ Th17 cells than that in
WT cells. Consistent with our findings, a recent study also
reported that IL-1 signaling maintains Th17 cells in the absence
of TCR stimuli (Chung et al., 2009). Thus, whereas IL-1 signaling
contributes to tissue immunity mediated by Th17 cells by
promoting Th17 cell differentiation and maintenance, SIGIRR-
modulated IL-1-induced mTOR pathway is essential to ensure
a stringent control for the proliferation of potentially pathogenic
Th17 cells. The fact that p38 and JNK inhibitors reduced IL-1-
induced IL-17 production in WT and Sigirr/ Th17 cells indi-
cates that these MAPKs are also required for IL-1-induced
Th17 cell effector function. Future studies are required to identify
the specific substrates of p38 and JNK that are critical for Th17
cell function.
We found that IL-1-mediated disruption of TSC1-TSC2
complex was greatly reduced in IRAK1-deficient cells derived
from 293-IL-1R cells, indicating that IL-1-induced IRAK1-
dependent mTOR activation is also through the disruption of
TSC1-TSC2 complex. Consistent with the negative regulation
of IRAK1 activation by SIGIRR, SIGIRR overexpression sup-
pressed IL-1-induced IRAK1 modification as well as the disrup-
tion of TSC1-TSC2. IKKb interacts with and phosphorylates
TSC1, resulting in suppression of TSC1, which plays a critical
role in IL-1-mediated mTOR activation (Lee et al., 2007).
Because IRAK4 and IRAK are known to mediate the IL-1-
induced IKKb activation, it is possible that IRAK4 and IRAK1
mediate mTOR activation through the activation of IKKb. Futurestudies are required to elucidate the detailed signaling cascade
for IL-1-induced IRAK4 and IRAK1-mediated mTOR activation.
We have defined the molecular mechanisms for Th17 cell
survival and competition for resources in vivo, which explains
why Th17 cells are completely absent in IL-1R-deficient mice
(Sutton et al., 2006). Compared to in vitro cultures, activating
CD4+ T helper cells in lymph nodes are exposed to relatively
low nutrient and antigen load. In this restrictive in vivo environ-
ment, IL-1 activation of the mTOR (nutrient sensor and cell cycle
regulator), p38, and JNK pathways enable Th17 cells to divide
faster and dominate an immune response compared to Th1 cells
that might have the same antigenic specificity. Hence, presence
of IL-1 during an inflammatory response will give Th17 cells
important survival and functional advantages over other T cell
subsets. In this study, we also identified SIGIRR as the key regu-
lator of IL-1 function in Th17 cells. Our earlier studies have shown
that SIGIRR can regulate innate immunity; however, as demon-
strated in the present study, SIGIRR is expressed on Th17 cells
and directly regulates adaptive immunity. In support of this,
recent studies have demonstrated critical roles of SIGIRR in
modulating lupus autoantigen priming and antigen-specific anti-
microbial responses (Bozza et al., 2008; Lech et al., 2008). Based
on these observations, we propose that SIGIRR is an important
negative ‘‘feedback switch’’ that prevents detrimental autoim-
mune and chronic inflammatory responses. Given the potency
of rapamycin for blockade of SIGIRR-IL-1-regulated Th17 cell
proliferation and cytokine production, it may be feasible to
consider this well-developed drug and related compounds for
treatment of autoimmune and chronic inflammatory diseases.
EXPERIMENTAL PROCEDURES
Mice
Il1r1/ andRag1/mice were purchased from Jackson Laboratory. Sigirr/
mice were generated as described (Wald et al., 2003). The CD2-SIGIRR
construct contains an EcoRI-BamHI cDNA fragment, coding for the SIGIRR
protein, inserted between 5 kilobase (kb) upstream and 5.5 kb downstream
flanking sequences of the human CD2 gene (Lang et al., 1988). A Flag tag
was included at the N terminus of SIGIRR to distinguish the transgene from
the endogenous gene. The founders that carry the SIGIRR transgene were
identified by genomic Southern analysis with SIGIRR cDNA as probes. SIGIRR
transgenic mice (CD2-SIGIRR) were bred to Sigirr/ mice to generate
SIGIRR-TG-KO mice. Mice were housed in animal facility (SPF condition) at
the Cleveland Clinic Foundation in compliance with the guidelines set by Insti-
tutional Animal Care and Use Committee.
T Cell Differentiation
Naive CD4+CD44lo T cells from Sigirr/, C57BL/6, and Il1r1/mice were
sorted by flow cytometry and activated with 1 mg/ml anti-CD3 and splenic
APCs in the presence of 5 ng/ml TGF-b and 10 ng/ml IL-6 (Peprotech). For
anti-CD3- and anti-CD28-stimulated differentiation, naive sorted CD4+CD44lo
T cells were activated with plate-bound 1 mg/ml anti-CD3 and 1 mg/ml anti-
CD28 and in the presence of 5 ng/ml TGF-b (Peprotech), 20 ng/ml IL-6 (Pepro-
tech), anti-IL-4 (11B11), 5mg/ml anti-IFN-g (XMG 1.2), 10 ng/ml IL-1b (National
Cancer Institute), or combination of these stimuli. 3 days after activation, cyto-
kines in the supernatant were measured by ELISA. For intracellular staining,
cells were stimulated with PMA and ionomycin in the presence of Golgi-stop
for 4 hr, after which IL-17- and IFN-g-producing cells were analyzed with intra-
cellular staining.
Transfection, Coimmunoprecipitations, and Immunoblots
Procedures for transfection, coimmunoprecipitations, and immunoblots with
293 cells were previously described (Yao et al., 2007). Antibodies used in thisImmunity 32, 54–66, January 29, 2010 ª2010 Elsevier Inc. 63
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IRAK1 (Santa Cruz), p-4EBP1, 4EBP1, p-IkBa, p-JNK, p-p38, p-mTOR,
mTOR, p-S6, TSC1, TSC2 (Cell Signaling), and GAPDH (Ambion).
EAE Induction and Adoptive Transfer Experiment
Procedures for EAE induction and adoptive transfer experiment were previ-
ously described (Qian et al., 2007). For EAE induction of Rag1/ mice, CD4+
T cells from wild-type and Sigirr/mice were sorted by AutoMacs and
intravenousely transferred into Rag1/mice (73 106 cells/transfer). One day
later, the recipient mice were immunized with MOG(35-55) as described above.
Quantitative Real-Time RT-PCR
Expression of the genes encoding IL-17A, IL-23R, IL-22, IL-21, IL-10, and
IRF-4 were quantified with the SYBER Green PCR Master Mix kit (Applied
Biosystems) with primer pairs selected for amplification of each individual
cytokine: Il17a, 50-CTCCACCGCAATGAAGAC-30 and 50-CTTTCCCTCCGCA
TTGAC-30; Il23r, 50-TTTTGTCGGGAATGGTCTTC-30 and 50-GCCACTTTGGG
ATCATCAGT-30; Il22, 50-TCATCGGGGAGAAACTGTTC-30 and 50-CATGTAG
GGCTGGAACCTGT-30; Il10, 50-TGAATTCCCTGGGTGAGAAG-30 and 50-TTC
ATGGCCTTGTAGACACCT-30; Il21, 50-CGCCTCCTGATTAGACTTCG-30 and
50-TTGAGTTTGGCCTTCTGAAAA-30; b-actin, 50-GGTCATCACTATTGGCAA
CG-30 and 50-ACGGATGTCAACGTCACACT-30; Irf4, 50-TCCTCTGGATGGC
TCCAGATGG-30, and 50-CACCAAAGCACAGAGTCACCTG-30. Relative gene
expression was determined as the ratio of cytokine to b-actin gene expression
levels for each sample.
Proliferation
Th17 cells were cultured in 96-well flat-bottom microtiter Falcon plates (BD
Labware) at 20 3 103 cells/well in DMEM (Mediatech CellGro) supplemented
with 10% FBS (HyClone), 5% HEPES buffer, 2% L-glutamine, and 1% peni-
cillin/streptomycin (Invitrogen Life Technologies). IL-1b was added in serial
dilutions to triplicate wells with negative control wells (without IL-1b). Cells
were cultured at a final volume of 200 ml/well. In some wells, rapmaycin
(50 nM) (Sigma) was added. After incubation for 96 hr, wells were pulsed
with [methyl-3H]thymidine (1.0 mCi/well, specific activity 6.7 Ci/mM; New
England Nuclear) and harvested 16 hr later by aspiration onto glass fiber filters.
For proliferation assay, levels of incorporated radioactivity were determined by
scintillation spectrometry. Results are expressed as mean cpm of experi-
mental cultures with IL-1b divided by mean cpm of cultures without IL-1b
(stimulation index).
Retroviral Infection
Frap1fl/fl naive T cells were sorted and differentiated into Th17 cells on anti-
CD3- and anti-28-coated plate as described above. After differentiation,
Th17 cells were rested for 2 days and reactivated with 0.2 mg/ml anti-CD3
and splenic APCs in the presence of 5 ng/ml TGF-b (Peprotech) and 10 ng/ml
IL-6 (Peprotech). Twenty-four hours after activation, the cells were infected by
retroviruses expressing either Cre-GFP (a gift from W. Paul at National Insti-
tutes of Health) or control empty vector (containing only IRES-GFP). Four
days after infection, the cells were washed; CD4+GFP+ cells were sorted
and cultured in the presence and absence of IL-1 for 3 days. At the end of
3 days, GFP+ cells were analyzed for cell proliferation by thymidine incorpora-
tion assay.
Statistics
ANOVA was used for EAE clinical score studies. The Student’s t test was used
to assess all other statistical values. p values were determined and error bars
represent standard error of the mean (SEM).
SUPPLEMENTAL INFORMATION
Supplemental Information includes one figure and can be found with this
article online at doi:10.1016/j.immuni.2009.12.003.
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